Superworth

Curis price to book ratio CRIS

Market value divided by the book value of the company's net assets, since 2011.

Today, Oct 23, 2026
0.2×
10-year median
4.1×
Against its 10-year history
0th
percentile: 0 is its lowest day, 100 its highest
10-year range
0.2× to 72.8×
Peer median
0.6×

Curis' price to book ratio is 0.2× as of Oct 23, 2026.

That is below its ten-year median of 4.1×, lower than on 100% of days in the last ten years.

Over that time it ranged from 0.2× in Oct 2026 to 72.8× in Nov 2018.

The median for 10 biotech stocks of a similar size is 0.6×.

Price to book ratio over time

The dashed line is the 10-year median and the shaded band the middle half of its days.

Open the interactive chart, with overlays and comparisons

Year by year

YearEnd of yearLowHigh
2026 so far0.2×0.2×4.4×
2025n/m a value too high to mean anything
20243.8×2.0×9.8×
20232.5×0.9×3.2×
20221.0×0.9×3.2×
20214.2×4.0×10.8×
2020n/m a value too high to mean anything
201960.6×37.1×61.4×
201832.1×2.7×72.8×
20173.8×3.8×33.7×
201611.4×2.4×12.5×
20154.9×3.1×10.7×
20143.2×2.7×6.8×
20135.8×4.9×11.4×
20125.9×5.3×12.2×
201111.1×5.9×11.1×

Against its peers

Companies in Biotechnology nearest Curis' size, closest first, today.

CompanyPrice to book ratio
CRISCuris0.2×
SLXNSilexion Therapeutics23.9×
CLDICalidi Biotherapeutics0.5×
VIVSVivoSim Labs, INC.n/m
PMCBPharmaCyte Biotech0.1×
LIMNLiminatus Pharma13.1×
AIMAIM ImmunoTech0.6×
CELZCreative Medical Technology0.6×
SNTISenti Biosciencesn/m
INABIN8BIO0.6×
INTSIntensity Therapeutics1.2×
Peer median0.6×

What the price to book ratio tells you

Market value divided by the accounting value of the company's net assets. Below 1 means the market values the business at less than what it owns on paper.

Book value misses brands, software and people, so asset-light companies always look expensive on it. Most useful for banks and industrials.

More on Curis

Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.